Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

CNS drugs

Soyka M.
PMID: 27520754
CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004.

Most psychotropic drugs, such as antipsychotics, lithium and tricyclic antidepressants, do not improve alcohol (ethanol) abstinence rates, at least in alcohol-dependent patients who do not have a comorbid psychiatric disorder. In recent years, numerous studies have been published that...

Cite
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997;7(4):313-27doi: 10.2165/00023210-199707040-00004.
Soyka, M. (1997). Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS drugs, 7(4), 313-27. https://doi.org/10.2165/00023210-199707040-00004
Soyka, M. "Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities." CNS drugs vol. 7,4 (1997): 313-27. doi: https://doi.org/10.2165/00023210-199707040-00004
Soyka M. Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities. CNS Drugs. 1997 Apr;7(4):313-27. doi: 10.2165/00023210-199707040-00004. PMID: 27520754.
Copy Download .nbib Format: NLM
Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist.

Drugs of today (Barcelona, Spain : 1998)

Cole P, Rabasseda X.
PMID: 12783088
Drugs Today (Barc). 2001 Mar;37(3):159-171. doi: 10.1358/dot.2001.37.3.614851.

Eletriptan is a member of the triptan family of selective serotonin receptor agonists. These act against migraine by inducing vasoconstriction of the meningeal arteries. In pharmacological tests, eletriptan has shown high affinity for the 5-HT(1B/1D) receptors, which have been...

Cite
Cole P, Rabasseda X. Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist. Drugs Today (Barc). 2001;37(3):159-171doi: 10.1358/dot.2001.37.3.614851.
Cole, P., & Rabasseda, X. (2001). Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist. Drugs of today (Barcelona, Spain : 1998), 37(3), 159-171. https://doi.org/10.1358/dot.2001.37.3.614851
Cole, P., and Rabasseda, X.. "Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist." Drugs of today (Barcelona, Spain : 1998) vol. 37,3 (2001): 159-171. doi: https://doi.org/10.1358/dot.2001.37.3.614851
Cole P, Rabasseda X. Migraine headache treatment with eletriptan, a second-generation serotonin receptor agonist. Drugs Today (Barc). 2001 Mar;37(3):159-171. doi: 10.1358/dot.2001.37.3.614851. PMID: 12783088.
Copy Download .nbib Format: NLM
Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.

Journal of pain research

Negro A, Koverech A, Martelletti P.
PMID: 29563831
J Pain Res. 2018 Mar 08;11:515-526. doi: 10.2147/JPR.S132833. eCollection 2018.

Migraine is an important socioeconomic burden and is ranked the sixth cause of years of life lost because of disability in the general population and the third cause of years of life lost in people younger than 50 years....

Cite
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515-526doi: 10.2147/JPR.S132833.
Negro, A., Koverech, A., & Martelletti, P. (2018). Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. Journal of pain research, 11515-526. https://doi.org/10.2147/JPR.S132833
Negro, Andrea, et al. "Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential." Journal of pain research vol. 11 (2018): 515-526. doi: https://doi.org/10.2147/JPR.S132833
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018 Mar 08;11:515-526. doi: 10.2147/JPR.S132833. eCollection 2018. PMID: 29563831; PMCID: PMC5848843.
Copy Download .nbib Format: NLM
Uncommon side effects of common drugs in patients with familial dysautonomia.

Pharmacoepidemiology and drug safety

Perl L, Hakimian D, Maayan C, Rekhtman D, Fried E, Salmon-Divon M, Sapozhnikov DM, Cheishvili D.
PMID: 34245206
Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):128-140. doi: 10.1002/pds.5326. Epub 2021 Jul 16.

PURPOSE: Patients with the autosomal recessive disorder of familial dysautonomia typically exhibit exacerbated adverse side effects to many common drugs. We aimed to catalog these adverse effects - with a focus on common drugs that are frequently administered to...

Cite
Perl L, Hakimian D, Maayan C, et al. Uncommon side effects of common drugs in patients with familial dysautonomia. Pharmacoepidemiol Drug Saf. 2021;31(2):128-140doi: 10.1002/pds.5326.
Perl, L., Hakimian, D., Maayan, C., Rekhtman, D., Fried, E., Salmon-Divon, M., Sapozhnikov, D. M., & Cheishvili, D. (2022). Uncommon side effects of common drugs in patients with familial dysautonomia. Pharmacoepidemiology and drug safety, 31(2), 128-140. https://doi.org/10.1002/pds.5326
Perl, Liat, et al. "Uncommon side effects of common drugs in patients with familial dysautonomia." Pharmacoepidemiology and drug safety vol. 31,2 (2022): 128-140. doi: https://doi.org/10.1002/pds.5326
Perl L, Hakimian D, Maayan C, Rekhtman D, Fried E, Salmon-Divon M, Sapozhnikov DM, Cheishvili D. Uncommon side effects of common drugs in patients with familial dysautonomia. Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):128-140. doi: 10.1002/pds.5326. Epub 2021 Jul 16. PMID: 34245206.
Copy Download .nbib Format: NLM
ePrescribing: Reducing Costs through In-Class Therapeutic Interchange.

Applied clinical informatics

Stenner SP, Chakravarthy R, Johnson KB, Miller WL, Olson J, Wickizer M, Johnson NN, Ohmer R, Uskavitch DR, Bernard GR, Neal EB, Lehmann CU.
PMID: 27966005
Appl Clin Inform. 2016 Dec 14;7(4):1168-1181. doi: 10.4338/ACI-2016-09-RA-0160.

INTRODUCTION: Spending on pharmaceuticals in the US reached $373.9 billion in 2014. Therapeutic interchange offers potential medication cost savings by replacing a prescribed drug for an equally efficacious therapeutic alternative.METHODS: Hard-stop therapeutic interchange recommendation alerts were developed for four...

Cite
Stenner SP, Chakravarthy R, Johnson KB, et al. ePrescribing: Reducing Costs through In-Class Therapeutic Interchange. Appl Clin Inform. 2016;7(4):1168-1181doi: 10.4338/ACI-2016-09-RA-0160.
Stenner, S. P., Chakravarthy, R., Johnson, K. B., Miller, W. L., Olson, J., Wickizer, M., Johnson, N. N., Ohmer, R., Uskavitch, D. R., Bernard, G. R., Neal, E. B., & Lehmann, C. U. (2016). ePrescribing: Reducing Costs through In-Class Therapeutic Interchange. Applied clinical informatics, 7(4), 1168-1181. https://doi.org/10.4338/ACI-2016-09-RA-0160
Stenner, Shane P, et al. "ePrescribing: Reducing Costs through In-Class Therapeutic Interchange." Applied clinical informatics vol. 7,4 (2016): 1168-1181. doi: https://doi.org/10.4338/ACI-2016-09-RA-0160
Stenner SP, Chakravarthy R, Johnson KB, Miller WL, Olson J, Wickizer M, Johnson NN, Ohmer R, Uskavitch DR, Bernard GR, Neal EB, Lehmann CU. ePrescribing: Reducing Costs through In-Class Therapeutic Interchange. Appl Clin Inform. 2016 Dec 14;7(4):1168-1181. doi: 10.4338/ACI-2016-09-RA-0160. PMID: 27966005; PMCID: PMC5228150.
Copy Download .nbib Format: NLM
Opioid-induced respiratory depression: reversal by non-opioid drugs.

F1000prime reports

van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M.
PMID: 25343036
F1000Prime Rep. 2014 Sep 04;6:79. doi: 10.12703/P6-79. eCollection 2014.

The human body is critically dependent on the ventilatory control system for adequate uptake of oxygen and removal of carbon dioxide (CO2). Potent opioid analgesics, through their actions on μ-opioid receptor (MOR) expressed on respiratory neurons in the brainstem,...

Cite
van der Schier R, Roozekrans M, van Velzen M, et al. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep. 2014;6:79doi: 10.12703/P6-79.
van der Schier, R., Roozekrans, M., van Velzen, M., Dahan, A., & Niesters, M. (2014). Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000prime reports, 679. https://doi.org/10.12703/P6-79
van der Schier, Rutger, et al. "Opioid-induced respiratory depression: reversal by non-opioid drugs." F1000prime reports vol. 6 (2014): 79. doi: https://doi.org/10.12703/P6-79
van der Schier R, Roozekrans M, van Velzen M, Dahan A, Niesters M. Opioid-induced respiratory depression: reversal by non-opioid drugs. F1000Prime Rep. 2014 Sep 04;6:79. doi: 10.12703/P6-79. eCollection 2014. PMID: 25343036; PMCID: PMC4173639.
Copy Download .nbib Format: NLM
5-HT.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Ochi S, Mori T, Iga JI, Ueno SI.
PMID: 34294620
Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):514-520. doi: 10.9758/cpn.2021.19.3.514.

OBJECTIVE: To investigate the efficacy of tandospirone, an azapirone anxiolytic similar to buspirone that is used in Japan, for behavioral and psychological symptoms of dementia (BPSD), especially in oldest-old patients.METHODS: This was an open-label observational study involving residents with...

Cite
Ochi S, Mori T, Iga JI, et al. 5-HT. Clin Psychopharmacol Neurosci. 2021;19(3):514-520doi: 10.9758/cpn.2021.19.3.514.
Ochi, S., Mori, T., Iga, J. I., & Ueno, S. I. (2021). 5-HT. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 19(3), 514-520. https://doi.org/10.9758/cpn.2021.19.3.514
Ochi, Shinichiro, et al. "5-HT." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 19,3 (2021): 514-520. doi: https://doi.org/10.9758/cpn.2021.19.3.514
Ochi S, Mori T, Iga JI, Ueno SI. 5-HT. Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):514-520. doi: 10.9758/cpn.2021.19.3.514. PMID: 34294620; PMCID: PMC8316653.
Copy Download .nbib Format: NLM
Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity.

Anesthesiology

van der Schrier R, Dahan JDC, Boon M, Sarton E, van Velzen M, Niesters M, Dahan A.
PMID: 34958670
Anesthesiology. 2021 Dec 27; doi: 10.1097/ALN.0000000000004096. Epub 2021 Dec 27.

Opioids may produce life-threatening respiratory depression and death from their actions at the opioid receptors within the brainstem respiratory neuronal network. Since there is an increasing number of conditions where the administration of the opioid receptor antagonist naloxone is...

Cite
van der Schrier R, Dahan JDC, Boon M, et al. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity. Anesthesiology. 2021;doi: 10.1097/ALN.0000000000004096.
van der Schrier, R., Dahan, J. D. C., Boon, M., Sarton, E., van Velzen, M., Niesters, M., & Dahan, A. (2021). Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity. Anesthesiology, . https://doi.org/10.1097/ALN.0000000000004096
van der Schrier, Rutger, et al. "Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity." Anesthesiology vol. (2021). doi: https://doi.org/10.1097/ALN.0000000000004096
van der Schrier R, Dahan JDC, Boon M, Sarton E, van Velzen M, Niesters M, Dahan A. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity. Anesthesiology. 2021 Dec 27; doi: 10.1097/ALN.0000000000004096. Epub 2021 Dec 27. PMID: 34958670.
Copy Download .nbib Format: NLM
Uncommon side effects of common drugs in patients with familial dysautonomia.

Pharmacoepidemiology and drug safety

Perl L, Hakimian D, Maayan C, Rekhtman D, Fried E, Salmon-Divon M, Sapozhnikov DM, Cheishvili D.
PMID: 34245206
Pharmacoepidemiol Drug Saf. 2021 Jul 10; doi: 10.1002/pds.5326. Epub 2021 Jul 10.

PURPOSE: Patients with the autosomal recessive disorder of familial dysautonomia typically exhibit exacerbated adverse side effects to many common drugs. We aimed to catalog these adverse effects - with a focus on common drugs that are frequently administered to...

Cite
Perl L, Hakimian D, Maayan C, et al. Uncommon side effects of common drugs in patients with familial dysautonomia. Pharmacoepidemiol Drug Saf. 2021;doi: 10.1002/pds.5326.
Perl, L., Hakimian, D., Maayan, C., Rekhtman, D., Fried, E., Salmon-Divon, M., Sapozhnikov, D. M., & Cheishvili, D. (2021). Uncommon side effects of common drugs in patients with familial dysautonomia. Pharmacoepidemiology and drug safety, . https://doi.org/10.1002/pds.5326
Perl, Liat, et al. "Uncommon side effects of common drugs in patients with familial dysautonomia." Pharmacoepidemiology and drug safety vol. (2021). doi: https://doi.org/10.1002/pds.5326
Perl L, Hakimian D, Maayan C, Rekhtman D, Fried E, Salmon-Divon M, Sapozhnikov DM, Cheishvili D. Uncommon side effects of common drugs in patients with familial dysautonomia. Pharmacoepidemiol Drug Saf. 2021 Jul 10; doi: 10.1002/pds.5326. Epub 2021 Jul 10. PMID: 34245206.
Copy Download .nbib Format: NLM
Serotonin receptors Therapeutic prospects in cardiovascular disease.

Trends in cardiovascular medicine

Connor HE, Humphrey PP, Feniuk W.
PMID: 21239312
Trends Cardiovasc Med. 1991 Jul-Aug;1(5):205-10. doi: 10.1016/1050-1738(91)90039-H.

Serotonin is widely distributed throughout the body, can have potent and profound effects on the cardiovascular system, and may be involved in the pathophysiology of several cardiovascular disease states. Recent advances in the classification of serotonin receptors, along with...

Cite
Connor HE, Humphrey PP, Feniuk W. Serotonin receptors Therapeutic prospects in cardiovascular disease. Trends Cardiovasc Med. 1991;1(5):205-10doi: 10.1016/1050-1738(91)90039-H.
Connor, H. E., Humphrey, P. P., & Feniuk, W. (1991). Serotonin receptors Therapeutic prospects in cardiovascular disease. Trends in cardiovascular medicine, 1(5), 205-10. https://doi.org/10.1016/1050-1738(91)90039-H
Connor, H E, et al. "Serotonin receptors Therapeutic prospects in cardiovascular disease." Trends in cardiovascular medicine vol. 1,5 (1991): 205-10. doi: https://doi.org/10.1016/1050-1738(91)90039-H
Connor HE, Humphrey PP, Feniuk W. Serotonin receptors Therapeutic prospects in cardiovascular disease. Trends Cardiovasc Med. 1991 Jul-Aug;1(5):205-10. doi: 10.1016/1050-1738(91)90039-H. PMID: 21239312.
Copy Download .nbib Format: NLM
LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice.

Frontiers in pharmacology

Alper K, Dong B, Shah R, Sershen H, Vinod KY.
PMID: 30233372
Front Pharmacol. 2018 Aug 31;9:994. doi: 10.3389/fphar.2018.00994. eCollection 2018.

There is a substantive clinical literature on classical hallucinogens, most commonly lysergic acid diethylamide (LSD) for the treatment of alcohol use disorder. However, there has been no published research on the effect of LSD on alcohol consumption in animals....

Cite
Alper K, Dong B, Shah R, et al. LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice. Front Pharmacol. 2018;9:994doi: 10.3389/fphar.2018.00994.
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. (2018). LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice. Frontiers in pharmacology, 9994. https://doi.org/10.3389/fphar.2018.00994
Alper, Kenneth, et al. "LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice." Frontiers in pharmacology vol. 9 (2018): 994. doi: https://doi.org/10.3389/fphar.2018.00994
Alper K, Dong B, Shah R, Sershen H, Vinod KY. LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice. Front Pharmacol. 2018 Aug 31;9:994. doi: 10.3389/fphar.2018.00994. eCollection 2018. PMID: 30233372; PMCID: PMC6127266.
Copy Download .nbib Format: NLM
Drugs in the pipeline for the obesity market.

Journal of diabetes science and technology

Klonoff DC, Greenway F.
PMID: 19885278
J Diabetes Sci Technol. 2008 Sep;2(5):913-8. doi: 10.1177/193229680800200525.

Obesity is a major public health problem. For many obese patients, diet and exercise are an inadequate treatment and bariatric surgery may be too extreme of a treatment. As with many other chronic diseases, pharmacologic treatment may be an...

Cite
Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. J Diabetes Sci Technol. 2008;2(5):913-8doi: 10.1177/193229680800200525.
Klonoff, D. C., & Greenway, F. (2008). Drugs in the pipeline for the obesity market. Journal of diabetes science and technology, 2(5), 913-8. https://doi.org/10.1177/193229680800200525
Klonoff, David C, and Greenway, Frank. "Drugs in the pipeline for the obesity market." Journal of diabetes science and technology vol. 2,5 (2008): 913-8. doi: https://doi.org/10.1177/193229680800200525
Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. J Diabetes Sci Technol. 2008 Sep;2(5):913-8. doi: 10.1177/193229680800200525. PMID: 19885278; PMCID: PMC2769782.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries